1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data

 
• By Alaric DeArment

Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.

T-cells attacking cancer_1200x675
Merck and Eisai published data in NEJM from the KEYNOTE-775 study of Keytruda/Lenvima in endometrial carcinoma • Source: Shutterstock

Newly published data from a study combining Merck & Co., Inc.’s PD-1 inhibitor Keytruda (pembrolizumab) and Eisai Co., Ltd.’s multiple tyrosine kinase inhibitor Lenvima (lenvatinib) in endometrial carcinoma adds to Keytruda’s growing repertoire of data in women’s cancers. With recent approvals in key settings of cervical cancer and triple-negative breast cancer (TNBC), Keytruda has taken a lead in cancers affecting women, even as other players played catch-up or stumbled.

Data from the Phase III KEYNOTE-775 study in patients with advanced endometrial carcinoma were published on 20 January in the...

More from Anticancer

More from Therapy Areas

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.